SCHEMBL560686

SCHEMBL560686

O=C1C[C@H](c2ccc(Cl)cc2)CN1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.57
PDE4A P27815 6/20 0.53
ALDH1A1 P00352 3/20 0.53
PDE4B Q07343 2/20 0.53
PDE4C Q08493 2/20 0.53
PDE4D Q08499 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C19 P33261 1/20 0.53
PKM P14618 1/20 0.53
GAA P10253 2/20 0.51
POLB P06746 1/20 0.50
ALOX12 P18054 1/20 0.50
HTT P42858 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HSD17B10 Q99714 1/20 0.50
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
SLC6A2 P23975 1/20 0.47
SLC6A4 P31645 1/20 0.47
SLC6A3 Q01959 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL657357 1.00 TSHR (0.57) TSHRPDE4AALDH1A1PDE4BPDE4C
SCHEMBL22831445 1.00 TSHR (0.57) TSHRPDE4AALDH1A1PDE4BPDE4C
SCHEMBL9669985 0.98 TSHR (0.55) TSHRPDE4AALDH1A1PDE4BPDE4C
SCHEMBL20001268 0.81 HTR3A (0.53) TSHRALDH1A1CYP1A2CYP2C19PKM
SCHEMBL20177606 0.81 TSHR (0.57) TSHRPDE4AALDH1A1PDE4BPDE4C
SCHEMBL20475320 0.81 TSHR (0.57) TSHRPDE4AALDH1A1PDE4BPDE4C
SCHEMBL10200945 0.81 TSHR (0.57) TSHRPDE4AALDH1A1PDE4BPDE4C
SCHEMBL481990 0.81 TSHR (0.57) TSHRPDE4AALDH1A1PDE4BPDE4C
SCHEMBL18590504 0.81 TSHR (0.61) TSHRPDE4AALDH1A1PDE4BPDE4C
SCHEMBL1269697 0.81 TSHR (0.57) TSHRPDE4AALDH1A1PDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120041848-A Method for electrochemically synthesizing chiral beta-ester nitrile and application of chiral beta-ester nitrile in synthesis of baclofen and rolipram 中国科学院化学研究所 2025-05-27 CN disclosed
US-11465135-B2 Bifunctional chiral organocatalytic compound having excellent enantioselectivity, preparation method therefor, and method for producing non-natural gamma-amino acid from nitro compound by using same KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2022-10-11 US disclosed
US-20200406243-A1 BIFUNCTIONAL CHIRAL ORGANOCATALYTIC COMPOUND HAVING EXCELLENT ENANTIOSELECTIVITY, PREPARATION METHOD THEREFOR, AND METHOD FOR PRODUCING NON-NATURAL GAMMA-AMINO ACID FROM NITRO COMPOUND BY USING SAME KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2020-12-31 US disclosed
WO-2018092916-A1 NITROGEN-CONTAINING POLYCYCLIC HETEROCYCLIC DERIVATIVE 宇部興産株式会社 2018-05-24 WO disclosed
EP-2298730-B1 METHOD OF PRODUCING PURIFIED OPTICALLY ACTIVE 4-AMINO-3-(SUBSTITUTED PHENYL)BUTANOIC ACID COMPOUND SUMITOMO CHEMICAL CO (JP) 2015-07-29 EP disclosed
US-8791295-B2 Method of producing purified optically acitve 4-amino-3-(substituted phenyl)butanoic acid compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-07-29 US disclosed
CN-102056891-B Method of producing purified optically active 4-amino-3-(substituted phenyl)butanoic acid compound SUMITOMO CHEMICAL CO 2014-06-25 CN disclosed
US-8344028-B2 Gamma-amino-butyric acid derivatives as GABAB receptor ligands XENOPORT, INC. (US) 2013-01-01 US disclosed
US-8293926-B2 Method of producing optically active 4-amino-3-substituted phenylbutanoic acid SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-23 US disclosed
US-8293926-B2 Method of producing optically active 4-amino-3-substituted phenylbutanoic acid SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-23 US disclosed
EP-2419401-A2 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAb RECEPTOR LIGANDS XenoPort, Inc. (US) 2012-02-22 EP disclosed
US-20120035139-A9 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS XENOPORT, INC. 2012-02-09 US disclosed
CN-102056891-A Method of producing purified optically active 4-amino-3-(substituted phenyl)butanoic acid compound SUMITOMO CHEMICAL CO 2011-05-11 CN disclosed
US-20110087049-A1 METHOD OF PRODUCING PURIFIED OPTICALLY ACITVE 4-AMINO-3-(SUBSTITUTED PHENYL)BUTANOIC ACID COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED 2011-04-14 US disclosed
EP-2298730-A1 METHOD OF PRODUCING PURIFIED OPTICALLY ACTIVE 4-AMINO-3-(SUBSTITUTED PHENYL)BUTANOIC ACID COMPOUND Sumitomo Chemical Company, Limited (JP) 2011-03-23 EP disclosed
US-20100267676-A1 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS XENOPORT, INC. 2010-10-21 US disclosed
WO-2010120370-A2 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS XENOPORT, INC. (US) 2010-10-21 WO disclosed
US-20090137819-A1 Method of Producing Optically Active 4-Amino-3-Substituted Phenylbutanoic Acid SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-05-28 US disclosed
US-20090137819-A1 Method of Producing Optically Active 4-Amino-3-Substituted Phenylbutanoic Acid SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-05-28 US disclosed
US-20090137819-A1 Method of Producing Optically Active 4-Amino-3-Substituted Phenylbutanoic Acid SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11465135-B2 Bifunctional chiral organocatalytic compound having excellent enantioselectivity, preparation method therefor, and method for producing non-natural gamma-amino acid from nitro compound by using same NOTUM, ALDH7A1, AADAT TSHR 4266/4885PDE4A 3790/4885ALDH1A1 612/4885
US-20100267676-A1 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS GABRB2, GABRB1, GABRB3 TSHR 729/4885PDE4A 1099/4885ALDH1A1 1314/4885
US-20200406243-A1 BIFUNCTIONAL CHIRAL ORGANOCATALYTIC COMPOUND HAVING EXCELLENT ENANTIOSELECTIVITY, PREPARATION METHOD THEREFOR, AND METHOD FOR PRODUCING NON-NATURAL GAMMA-AMINO ACID FROM NITRO COMPOUND BY USING SAME NOTUM, ALDH7A1, AADAT TSHR 4266/4885PDE4A 3790/4885ALDH1A1 612/4885
US-20090137819-A1 Method of Producing Optically Active 4-Amino-3-Substituted Phenylbutanoic Acid ALAD, ATP6V1B1, DAO TSHR 3212/4885PDE4A 346/4885ALDH1A1 1016/4885
US-20110087049-A1 METHOD OF PRODUCING PURIFIED OPTICALLY ACITVE 4-AMINO-3-(SUBSTITUTED PHENYL)BUTANOIC ACID COMPOUND ALAD, OR10J3, ACMSD TSHR 4176/4885PDE4A 590/4885ALDH1A1 566/4885
US-20120035139-A9 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS GABRB2, GABRB1, GABRB3 TSHR 729/4885PDE4A 1099/4885ALDH1A1 1314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.